https://www.tipranks.com/news/the-fly/masimo-price-target-raised-to-170-from-166-at-btig BTIG analyst Marie Thibault raised the firm’s price target on Masimo to $170 from $166 and keeps a Buy rating on the shares as part of a broader research note previewing Q3 results in MedTech. The sector had “solid returns” as Providers outperformed among healthcare sub-sectors at 10.5% for iShares U.S. Healthcare Providers ETF (IHF), and these results track largely in line with fundamental feedback during Q3 as procedure volumes have been healthy and demand is strong, the analyst tells investors in a research note. Channel checks in many sub-sectors also point to sustained procedure demand continuing into 2025 as demographics and low unemployment provide support, the firm added. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on MASI: Apple rethinking approach to headsets, Bloomberg reports Micron reports Q4 beat, Pfizer withdraws Oxbryta: Morning Buzz Masimo founder Kiani demands $400M in payouts after board ousting, FT says SAP under DOJ probe, Adobe sees record holiday season sales: Morning Buzz Masimo Announces Executive Shift and Strategic Business Review
Masimo price target raised to $170 from $166 at BTIG
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...